|
Characteristic
|
DS
|
SS
|
Between-group differences in change from baseline to 12 weeks
| |
|---|
|
Baseline
|
12 weeks
|
Baseline
|
12 weeks
|
|---|
|
M (SE)
|
M (SE)
|
M (SE)
|
M (SE)
|
M (SE)
|
95% CI [LCI, UCI]
|
t
a
|
df
|
p
|
|---|
|
Symptoms
|
|
MADRS (0-60)
|
26.1 (1.0)
|
14.8 (1.1)
|
24.7 (1.0)
|
20.5 (1.2)
|
7.1 (1.6)
|
3.9, 10.4
|
4.38
|
60.7
|
<.001
|
|
HADS – (D) (0-21)
|
10.0 (0.6)
|
5.3 (0.7)
|
9.2 (0.6)
|
6.8 (0.7)
|
2.3 (1.1)
|
0.2, 4.4
|
2.20
|
55.1
|
.032
|
|
HADS – (A) (0-21)
|
12.1 (0.6)
|
8.4 (0.6)
|
11.2 (0.6)
|
9.5 (0.7)
|
2.0 (0.9)
|
0.2, 3.9
|
2.19
|
59.0
|
.033
|
|
Mood
|
|
POMS (-32–200)
|
54.5 (6.0)
|
30.3 (6.5)
|
40.9 (5.8)
|
32.1 (6.7)
|
15.4 (9.9)
|
-4.6, 35.3
|
1.56
|
43.5
|
.127
|
|
Self-efficacy
|
|
GSE (10-40)
|
24.6 (1.0)
|
28.1 (1.0)
|
25.7 (1.0)
|
26.7 (1.1)
|
-2.4 (1.6)
|
-5.7, 0.9
|
-1.44
|
59.0
|
.156
|
|
Wellbeing
|
|
WHO-5 (0-25)
|
6.9 (0.8)
|
12.3 (0.9)
|
6.7 (0.8)
|
10.3 (1.0)
|
-1.8 (1.7)
|
-5.2, 1.6
|
-1.04
|
62.0
|
.304
|
|
Anthropometry
|
|
BMI
|
30.0 (1.4)
|
29.9 (1.4)
|
29.0 (1.4)
|
29.1 (1.4)
|
0.15 (0.27)
|
-0.4, 0.7
|
0.56
|
47.0
|
.579
|
|
Physical activity (IPAQ scores)
|
2307.7 (664.8)
|
2251.3 (645.9)
|
2509.4 (636.3)
|
2892.2 (636.3)
|
439.3 (1097.6)
|
-1757.2, 2635
|
0.40
|
58.9
|
.690
|
|
Diet
|
|
ModiMedDiet (0-120)
|
36.2 (2.5)
|
55.1 (2.8)
|
47.3 (2.6)
|
45.4 (2.9)
|
-20.7 (4.3)
|
-20.7, -12.1
|
-4.78
|
55.62
|
<.001
|
|
Biomarkers
|
|
Glucose (mmol/L)
|
4.5 (0.5)
|
4.7 (5.5)
|
5.4 (0.5)
|
5.5 (0.6)
|
-0.1 (4.3)
|
-0.9, 0.8
|
-0.10
|
48.5
|
.919
|
|
Cholesterol (mmol/L)
|
4.9 (0.2)
|
4.8 (0.2)
|
5.5 (0.2)
|
5.2 (0.2)
|
-0.2 (0.2)
|
-0.5, 0.2
|
-1.08
|
47.7
|
.287
|
|
Triglycerides (mmol/L)
|
1.3 (0.2)
|
1.2 (0.2)
|
1.4 (0.2)
|
1.5 (0.2)
|
0.2 (0.2)
|
-0.3, 0.7
|
0.88
|
53.4
|
.386
|
|
HDL cholesterol (mmol/L)
|
-1.5 (0.1)
|
1.5 (0.1)
|
1.4 (0.1)
|
1.3 (0.1)
|
-0.1 (0.1)
|
-0.2, 0.1
|
-1.11
|
47.7
|
.272
|
|
LDL cholesterol (mmol/L)
|
2.9 (0.2)
|
2.8 (0.1)
|
3.4 (0.2)
|
3.2 (0.2)
|
-0.1 (0.2)
|
-0.4, 0.3
|
-0.48
|
47.1
|
.636
|
|
Total saturates (% FA)
|
35.7 (0.5)
|
36.6 (0.5)
|
35.6 (0.5)
|
38.1 (0.6)
|
1.6 (1.0)
|
-0.5, 3.6
|
1.54
|
62.1
|
.128
|
|
Total monounsaturates (% FA)
|
23.2 (0.4)
|
22.2 (0.5)
|
22.8 (0.4)
|
23.2 (0.6)
|
1.4 (0.8)
|
-0.3, 3.1
|
1.69
|
55.4
|
.096
|
|
Total polyunsaturates (% FA)
|
41.1 (0.7)
|
41.3 (0.8)
|
41.6 (0.7)
|
38.6 (0.9)
|
-3.1 (1.3)
|
-5.7, 0.5
|
-2.41
|
54.9
|
.019
|
|
n6 (% PUFA)
|
14.6 (0.4)
|
14.5 (0.4)
|
14.3 (0.4)
|
12.8 (0.5)
|
-1.4 (0.8)
|
-3.0, 0.3
|
-1.69
|
62.1
|
.096
|
|
n3 (% PUFA)
|
6.9 (0.3)
|
6.8 (0.3)
|
6.5 (0.3)
|
7.2 (0.4)
|
0.9 (0.6)
|
-0.3, 2.1
|
1.57
|
57.8
|
.123
|
-
MADRS Montgomery-Åsberg Depression Rating Scale, HADS Hospital Anxiety and Depression Scale, POMS Profile of Mood States, GSE Generalized Self-Efficacy scale, WHO-5 WHO (Five) wellbeing index, BMI body mass index, FA fatty acids, PUFA polyunsaturated fatty acids
-
aDerived from planned comparison within mixed model repeated measures (MMRM) using all available data (baseline data n = 67, 12 week data n = 56) and based on unadjusted estimates
